Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
NCT06643000
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
60
Enrollment
OTHER_GOV
Sponsor class
Conditions
Non-small Cell Lung Cancer
Leptomeningeal Metastasis
EGFR Gene Mutation
Interventions
DRUG:
furmonertinib
Sponsor
Henan Cancer Hospital